| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1b/2 data readout example | Phase 1b/2 | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology | ||
Phase 1b/2 data readout example | Phase 1b/2 | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology | ||
Phase 1b/2 data readout example | Phase 1b/2 | — | Subscribe to access the data. | Antibody-Drug Conjugates (ADCs) | Oncology |
Recent Updates
Recently added Catalysts
Adagene Inc.$3.94
+0.09 (+2.34%)
C 52Pipeline Score Fair Value Pharma · Clinical
Market Cap
160.64 M
EPS
-0.37
P/E Ratio
-9.06 $
Value Trade
160.98 K
4.17 %
Week
-0.53 %
1 Month
17.74 %
3 Month
115.52 %
6 Month
-71.46 %
5 Year
-81.62 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
376.84 K
52 Week Range
1.30 - 4.75
% held by Insiders
11.02 %
% held by Institutions
18 %
Enterprise Value
108.93 M
Total Shares
47.39 M
Short %
4.4 %
Float Shares
42.17 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Adagene Inc.
276Total events
7Upcoming
43Tier-1 (high impact)
2020 – 2027Coverage
Upcoming catalysts 7
2027
T2Runway Guidance Update
Proceeds from Sanofi investment expected to extend cash runway into 2027
Event history 269
Jun 3, 2026
◆Oral PresentationPresentation
One-on-one meetings at Jefferies LLC Global Healthcare Conference
May 19, 2026
Apr 20, 2026
◆Poster PresentationADG126Presentation
Poster presentation at AACR 2026: Ph1b evaluation of ADG126 + pembrolizumab + fruquintinib in MSS CRC
advanced and metastatic microsatellite stable colorectal cancersource ↗
Apr 17, 2026
▲Poster PresentationADG126Presentation
Poster presentation at AACR 2026 for triple combination muzastotug + pembrolizumab + fruquintinib in MSS CRC
microsatellite stable colorectal cancersource ↗
Apr 14, 2026
▲Management ChangeCorporate
Peter Lebowitz appointed to Scientific and Strategic Advisory Board
Apr 2, 2026
Apr 2, 2026
▲Partnership / LicenseCorporate
Clinical collaboration with Incyte to evaluate muzastotug + INCA33890 in MSS CRC
Feb 25, 2026
Drug Pipeline Intelligence
C52
Pipeline Score $452M
Pipeline ValueFair Value
Valuation Signal7
Drugs Scored2.8x
rNPV / MCap Top 79%
Micro Cap (rank 192 of 911)
Percentile RankAdagene Inc. carries a moderate pipeline score (52/100), with $6.3B risk-adjusted pipeline value, led by ADG126 Mono in Advanced/Metastatic Solid Tumors (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ADG126 Mono Monoclonal antibody | Advanced/Metastatic Solid Tumors | Phase 1 | NCT04645069 | 9% | $1.7B | COMPLETED | 58 | - | - | May 17, 2024 | - | Aug 14, 2024 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
muzastotug Fast Track | hepatocellular carcinoma | Phase 1b/2 | 2026-04-17 | The triple combination of muzastotug (6 mg/kg Q6W), atezolizumab, and bevacizumab achieved a 66.7% overall response rate (ORR; 4/6) with a median progression-free survival (mPFS) of 8.2 months in a Phase 1b/2 trial for hepatocellular carcinoma patients. Read More | Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug's Potential as a Backbone Combination Therapy for Multiple Tumor Types Triple combination of muzastotug + atezolizumab + bevacizumab resulte Read More | |
muzastotug Fast Track | hepatocellular carcinoma | Phase 1b/2 | 2026-04-17 | The triple combination of muzastotug (6 mg/kg Q6W), atezolizumab, and bevacizumab achieved a 66.7% overall response rate (ORR; 4/6) with a median progression-free survival (mPFS) of 8.2 months in a Phase 1b/2 trial for hepatocellular carcinoma patients. Read More | Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug's Potential as a Backbone Combination Therapy for Multiple Tumor Types Triple combination of muzastotug + atezolizumab + bevacizumab resulte Read More | |
muzastotug Fast Track | hepatocellular carcinoma | Phase 1b/2 | 2026-04-17 | The triple combination of muzastotug (6 mg/kg Q6W), atezolizumab, and bevacizumab achieved a 66.7% overall response rate (ORR; 4/6) with a median progression-free survival (mPFS) of 8.2 months in a Phase 1b/2 trial for hepatocellular carcinoma patients. Read More | Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug's Potential as a Backbone Combination Therapy for Multiple Tumor Types Triple combination of muzastotug + atezolizumab + bevacizumab resulte Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ADAG
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ADAG Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ADAGAdagene to Participate in Two Upcoming Investor Conferences
Adagene Inc. has announced its participation in two upcoming investor conferences, the Stifel Annual Virtual Oncology Event and the Jefferies LLC Global Healthcare Conference, scheduled for May and June 2026, respectively. Senior management will engage in one-on-one meetings and presentations to discuss the company's advancements in antibody-based cancer therapies. The announcement underscores Adagene's commitment to innovation in immunotherapy, particularly through its SAFEbody technology and the ongoing clinical studies of its lead program, muzastotug. A webcast of the presentations will be available on the company's investor website following the events.
Read more →ADAGAdagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug's Potential as a Backbone Combination Therapy for Multiple Tumor Types Triple combination of muzastotug + atezolizumab + bevacizumab resulte
Adagene Inc. presented encouraging new data at the AACR annual meeting, highlighting the potential of muzastotug as a backbone therapy for multiple cancers. In clinical trials, a triple combination of muzastotug with atezolizumab and bevacizumab showed a significant increase in response rates compared to standard treatments in hepatocellular carcinoma. Additionally, in colorectal cancer, its combination with pembrolizumab and fruquintinib demonstrated a dose-dependent efficacy. The findings support the continued development of muzastotug and its therapeutic applications in challenging oncology settings.
Read more →ADAGAdagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board
Adagene Inc. has appointed Peter Lebowitz, MD, Ph.D., to its Scientific and Strategic Advisory Board. Lebowitz, known for his expertise in oncology and drug development, will guide the clinical advancement of Adagene's lead candidate, ADG126. His experience includes significant contributions to the development of numerous successful therapies during his tenure at Johnson & Johnson.
Read more →ADAG▼ -13.4%on this news
Confidential Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte's TGF R2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal
Adagene has entered a clinical collaboration with Incyte to evaluate the combination of its drug muzastotug (ADG126) with Incyte's TGF R2xPD-1 bispecific antibody (INCA33890) in patients with microsatellite stable colorectal cancer (MSS CRC). The Phase 1 study, set to begin in 2026, will focus on patients with and without liver metastases. This collaboration aims to enhance immunotherapy options for MSS CRC, a condition that is often resistant to existing treatments. Adagene will supply muzastotug, while Incyte will conduct the study.
Read more →ADAG▼ -13.4%on this news
Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs
Adagene Inc. has announced the pricing of its public offering of 18,666,000 American depositary shares at $3.75 each, aiming to raise approximately $70 million. The offering is set to close on April 6, 2026, pending customary conditions. Notable participation includes various investment firms, indicating strong market interest.
Read more →ADAG▲ +17.6%on this newsshared move
Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update In 2025, muzastotug showed 29% confirmed overall response rate (ORR) among 21 patients with MSS CRC in the 20 mg/kg dose cohorts Median overa
Adagene Inc. reported its financial results for the full year 2025 and provided updates on its clinical programs. The company's investigational therapy muzastotug demonstrated a 29% confirmed overall response rate among patients with MSS colorectal cancer, with an overall survival of 19.4 months for lower dose cohorts. Additionally, clinical tolerability appeared favorable, with no significant treatment-related adverse events reported across its patient population. Adagene also announced that its cash position as of December 31, 2025, stands at $74.5 million, projecting financial viability into early 2028.
Read more →ADAGAdagene’s Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA
Adagene Inc. announced that its drug muzastotug (ADG126) will be featured in two poster presentations at the AACR Annual Meeting 2026 in San Diego. The presentations will focus on its Phase 1b evaluation in colorectal cancer and results from the Morpheus Liver study in hepatocellular carcinoma. Adagene continues to advance its antibody-based therapies using its SAFEbody technology.
Read more →ADAGAdagene Provides Business Update and 2026 Objectives
Adagene Inc. announced a business update with a cash position of $74.5 million, expected to sustain operations until late 2027. The company is focused on advancing its lead program, muzastotug, which is in Phase 1b/2 studies for treating MSS metastatic colorectal cancer. CEO Peter Luo emphasized the potential of muzastotug as a next-generation therapy, integrating innovative approaches in cancer treatment.
Read more →ADAG▲ +13.8%on this news
Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126)
Adagene Inc. has received FDA Fast Track Designation for its drug muzastotug, aimed at treating microsatellite stable metastatic colorectal cancer in adults without liver metastases. This designation is based on positive clinical data demonstrating the drug's efficacy and safety when used with Merck's KEYTRUDA therapy. The company plans to advance its ongoing Phase 2 trial and is optimistic about the potential for muzastotug to improve patient outcomes significantly. The Fast Track status will allow for expedited development and review processes.
Read more →ADAGAdagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology
Adagene has entered a licensing agreement with Third Arc Bio to utilize its SAFEbody technology for developing two CD3 T cell engagers. Adagene will receive an upfront payment of $5 million and could earn up to $840 million in milestones, along with royalties on sales. This partnership aims to enhance the therapeutic index of T cell engagers targeting unique tumor-associated antigens.
Read more →ADAG▼ -7.3%on this news· ran to -22% by day 3
Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer
Adagene has initiated a Phase 2 clinical trial for muzastotug in combination with KEYTRUDA for microsatellite stable colorectal cancer. The first patient was dosed in October 2025, with the trial expected to complete by early 2027. The study aims to confirm the optimal dosing strategy and improve patient outcomes based on previous FDA discussions.
Read more →ADAGAdagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate
Adagene has amended its collaboration agreement with Exelixis to develop a new antibody-drug conjugate using its SAFEbody technology. This technology allows for targeted delivery of therapeutics to tumor cells while minimizing effects on healthy cells. Adagene is set to receive milestones and royalties from this partnership, which underscores the potential of its innovative approach in cancer treatment.
Read more →ADAGAdagene’s ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China
Adagene Inc. announced that its drug ADG126 will be highlighted in two presentations at the 2025 CSCO Meeting in Jinan, China. The presentations will focus on the promising results of ADG126 in combination with pembrolizumab for treating advanced microsatellite stable colorectal cancer. The drug has shown a significant objective response rate and a favorable safety profile, indicating potential for improved survival outcomes.
Read more →ADAGAdagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor
Adagene Inc. has appointed Dr. Axel Hoos as Executive Advisor, a notable figure in immuno-oncology. Dr. Hoos's expertise will support the advancement of Adagene's innovative antibody therapies, particularly ADG126, which targets CTLA-4. His leadership is expected to enhance the development of precision immunotherapy, especially for challenging cancer types.
Read more →ADAGAdagene to Participate in Two Investor Conferences in September
Adagene Inc. announced its participation in two investor conferences in September, where Chief Strategy Officer Mickael Chane-Du will engage in one-on-one meetings and a fireside chat. The conferences, H.C. Wainwright 27th Annual Global Investment Conference and Morgan Stanley 23rd Annual Global Healthcare Conference, will take place in New York. A webcast of the presentations will be available on the company's website.
Read more →ADAG▼ -13.6%on this news
Adagene Reports Six Months 2025 Financial Results and Provides Corporate Updates
Adagene Inc. reported its financial results for the first half of 2025, highlighting significant progress in its clinical trials for ADG126, which demonstrated a median overall survival of 19.4 months in microsatellite stable colorectal cancer patients. The company has aligned with the FDA on Phase 2 and Phase 3 trial designs and plans to start patient enrollment in the second half of 2025. Additionally, a strategic investment from Sanofi and new partnerships aim to bolster Adagene's research and development efforts.
Read more →ADAGAdagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA
Adagene Inc. announced a regulatory update following a Type B meeting with the FDA regarding its clinical development plan for muzastotug (ADG126) in microsatellite stable colorectal cancer. The FDA provided feedback on the Phase 2 trial design, including endpoints and dosing regimen. Patient enrollment for Phase 2 is expected to begin in the second half of 2025.
Read more →ADAGAdagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate
Adagene has partnered with ConjugateBio to develop novel bispecific antibody-drug conjugates (ADCs). Adagene will provide a proprietary antibody to enhance ConjugateBio's ADC development programs. This collaboration aims to leverage Adagene's advanced antibody discovery capabilities and is expected to significantly impact the ADC market, projected to reach over $30 billion by 2030.
Read more →ADAG▼ -5.1%on this news
Adagene announces up to $25 million strategic investment from Sanofi
Adagene Inc. has secured a strategic investment of up to $25 million from Sanofi to support its research and development efforts, particularly for the clinical development of muzastotug in colorectal cancer. Sanofi will also evaluate muzastotug in combination with other therapies in a phase 1/2 trial. This partnership underscores the potential of Adagene's SAFEbody platform.
Read more →ADAG▼ -5.1%on this newsshared move
Internal Adagene announces up to $25 million strategic investment from Sanofi - Sanofi to exercise option on third SAFEbody discovery program and sponsor combination clinical trial with muzastotug - Company expects proce
Adagene Inc. has announced a strategic investment of up to $25 million from Sanofi, which will facilitate the clinical development of muzastotug, an anti-CTLA-4 SAFEbody. Sanofi will also exercise its option on a new SAFEbody discovery program based on Adagene's technology. The investment is expected to extend Adagene's cash runway into 2027, supporting ongoing R&D efforts. The collaboration includes a clinical trial evaluating muzastotug in combination with other anticancer therapies.
Read more →ADAGAdagene to Present at Jefferies Global Healthcare Conference 2025
Adagene Inc. (Nasdaq: ADAG) will have its Chief Strategy Officer, Mickael Chane-Du, present at the upcoming Jefferies Global Healthcare Conference 2025. Scheduled for June 3-5 in New York, the event will include one-on-one investor meetings and a fireside chat. Adagene is focused on developing antibody-based cancer immunotherapies using its SAFEbody technology, aimed at improving safety and targeting in cancer treatments. The company's lead clinical program, ADG126, is currently undergoing phase 1b/2 trials for metastatic colorectal cancer.
Read more →ADAGAdagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting CTLA-4 inhi
Adagene Inc. announced updated data from its Phase 1b/2 study of ADG126 in combination with KEYTRUDA for treating advanced microsatellite stable colorectal cancer. The study reported a 29% overall response rate and fewer than 20% Grade 3 adverse events. The treatment regimen demonstrated promising overall survival, with responders maintaining treatment over significant durations. Future discussions with regulatory bodies are planned to discuss dosing regimens for the next phase of clinical development.
Read more →ADAGAdagene Appoints John Maraganore, Ph.D. as Executive Advisor
Adagene Inc. has appointed Dr. John Maraganore as Executive Advisor, aiming to leverage his extensive experience in biopharma to guide the company's strategic direction. Dr. Maraganore, former CEO of Alnylam, is expected to contribute to Adagene's growth and the advancement of its innovative cancer therapies. The company is known for its proprietary SAFEbody technology, which enhances the targeting of antibody therapies, and is currently developing ADG126, a novel therapy for metastatic colorectal cancer. This appointment aligns with Adagene's ongoing commitment to transforming cancer immunotherapy through advanced technology.
Read more →ADAGAdagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting
Adagene Inc. has announced a poster presentation for its drug ADG126 at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting on May 31, 2025. The abstract will focus on the safety and efficacy of ADG126, a masked anti-CTLA-4 SAFEbody, in combination with Pembrolizumab, particularly for patients with advanced MSS colorectal cancer. The company emphasizes its commitment to developing novel antibody-based therapies through advanced technologies. This opportunity signifies an important step forward in the company's clinical research and pipeline development.
Read more →ADAGAdagene to Present at Stifel’s 2025 Virtual Targeted Oncology Forum
Adagene Inc. has announced that its CEO, Peter Luo, Ph.D., will participate in one-on-one investor meetings and present at Stifel's 2025 Virtual Targeted Oncology Forum on April 8-9. The company focuses on the development of novel antibody-based therapies with its proprietary SAFEbody technology addressing safety concerns associated with traditional antibody treatments. Adagene is currently conducting phase 1b/2 clinical studies of its lead program, ADG126, aimed at treating Metastatic Microsatellite-stable Colorectal Cancer.
Read more →ADAG▲ +5%on this news
Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update Muzastotug Phase 2 dose expansion in MSS CRC with a 20 mg/kg loading dose regimen shows 33% overall response rate with four confirmed partial
Adagene Inc. reported its financial results for 2024, noting a cash balance of $85.2 million. The company highlighted the promising efficacy of ADG126, showing a 33% overall response rate in a Phase 2 study for patients with microsatellite stable colorectal cancer. Despite the positive clinical data, Adagene experienced a net loss of $33.4 million, a significant increase from the previous year, alongside a major decline in net revenue. The company is focused on advancing immunotherapy approaches using its SAFEbody technology and is pursuing strategic partnerships to enhance its pipeline.
Read more →ADAGAdagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit
Adagene Inc. announced its participation in the 11th Annual Immuno-Oncology 360° Summit, where it will present data on ADG126, a novel anti-CTLA-4 SAFEbody targeting metastatic colorectal cancer. The summit will take place in Boston on March 26, 2025, bringing together stakeholders from various sectors to discuss advancements in immuno-oncology. Adagene leverages advanced technologies in antibody development, with a focus on enhancing safety and efficacy in cancer treatments. The company's ongoing clinical trials aim to validate its innovative approach to immunotherapy.
Read more →ADAGAdagene to Present at Leerink’s Global Healthcare Conference 2025
Adagene Inc. (Nasdaq: ADAG) has announced its participation in the upcoming Leerink's Global Healthcare Conference 2025, where CEO Peter Luo will provide a corporate update. The conference is set for March 10-12 in Miami, with Adagene's presentation scheduled for March 12. The company is focused on developing novel antibody-based cancer immunotherapies, leveraging their advanced SAFEbody technology to enhance patient safety and treatment effectiveness.
Read more →ADAGAdagene Announces Investigator Initiated Phase 2 Trial for Neoadjuvant Muzastotug (ADG126) in Colorectal Cancer
Adagene Inc. has announced the initiation of an investigator initiated Phase 2 trial for ADG126, aimed at stage II and III colorectal cancer patients. Set to begin enrollment in April 2025, the trial will evaluate the combination of ADG126 and KEYTRUDA, with a primary focus on the rate of major pathological response. It will explore additional endpoints such as safety, tolerability, and the effects on the tumor microenvironment. The study is viewed as a strategic step in advancing immunotherapy into a neoadjuvant context, potentially enhancing patient outcomes.
Read more →ADAGAdagene Announces Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium Muzastotug (ADG126), an Anti-CTLA-4 SAFEbody
Adagene announced updated data from its Phase 1b/2 study of ADG126 in combination with KEYTRUDA for colorectal cancer at the ASCO GI Symposium. The latest results indicate an overall response rate of 33% in microsatellite stable colorectal cancer, with four partial responses noted among 12 patients. Importantly, no Grade 4/5 treatment-related adverse events were reported, and no patients discontinued treatment. The company plans to evaluate ADG126 in a broader patient population, including those with liver metastases, following these promising results.
Read more →ADAGAdagene to Announce Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium
Adagene Inc. announced it will present updated clinical data for ADG126 at the ASCO Gastrointestinal Cancers Symposium on January 25, 2025. The Phase 1b/2 study examines ADG126 in combination with Merck's KEYTRUDA in patients with microsatellite stable colorectal cancer (MSS CRC). The presentation will include initial results from a higher dosing strategy, emphasizing the potential of this combination therapy. A virtual event featuring experts will discuss the relevance of CTLA-4 targeting in this cancer type.
Read more →ADAGAdagene to Host Virtual KOL Event to Discuss Anti-CTLA-4 SAFEbody ADG126 in Advanced/Metastatic Microsatellite-Stable (MSS) Colorectal Cancer (CRC) on January 25, 2025
Adagene Inc. will host a virtual key opinion leader (KOL) event on January 25, 2025, focusing on the unmet needs in treating advanced microsatellite-stable colorectal cancer. The event will present data on the Phase 1b/2 study of ADG126, an anti-CTLA-4 SAFEbody, in combination with KEYTRUDA. Experts from notable institutions will discuss the importance of CTLA-4 targeting for achieving durable responses in this challenging cancer type.
Read more →ADAGAdagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
Adagene Inc. presented two significant poster sessions at the SITC 39th Annual Meeting, highlighting promising data for its masked anti-CTLA-4 SAFEbody ADG126. Findings indicate that ADG126 may offer superior therapeutic index and safety compared to existing therapies, particularly in combination with pembrolizumab for metastatic colorectal cancer patients. The poster was recognized as a top abstract, emphasizing its relevance and potential impact in cancer care. Ongoing studies are expected to provide further insights into the efficacy and safety profile of ADG126.
Read more →ADAGSECURITIES AND EXCHANGE COMMISSION
Adagene Inc. has submitted a report to the SEC containing significant updates regarding its therapeutic developments. The company presented two posters at the Society for Immunotherapy of Cancer's 39th Annual Meeting, detailing new insights into the therapeutic index of its Masked Anti-CTLA-4 SAFEbody, ADG126. The presentations also reinforce the clinical safety and efficacy of ADG126 both as a monotherapy and in combination with anti-PD-1 therapy.
Read more →ADAGAdagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
Adagene Inc. has announced that it will be presenting significant findings regarding its masked anti-CTLA-4 SAFEbody ADG126 (Muzastotug) at the Society for Immunotherapy of Cancer's 39th Annual Meeting in Houston from November 6-10, 2024. The presentations will focus on a study comparing the therapeutic index of ADG126 with its unmasked form and its combination with anti-PD-1 therapy in advanced colorectal cancer. Adagene's SAFEbody technology aims to improve safety and efficacy in antibody therapeutics, with clinical studies ongoing for ADG126.
Read more →ADAG▼ -21.2%on this news· ran to -36% by day 3
Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody ADG126 (Muzastotug) in Combination with KEYTRUDA (Pembrolizumab) in Advanced/Metastatic Microsatellite-stab
Adagene Inc. is presenting promising clinical results for its anti-CTLA-4 SAFEbody, ADG126, at the ESMO Congress. The combination of ADG126 with KEYTRUDA shows a promising overall response rate and median progression-free survival in patients with advanced/metastatic microsatellite-stable colorectal cancer. The therapy, which maintains a favorable safety profile, demonstrates significant potential for treating a larger population of patients, including those with liver metastases. Adagene plans to advance clinical development, based on these encouraging outcomes.
Read more →ADAGAdagene to Participate in Investor Conferences in September
Adagene Inc. (Nasdaq: ADAG) will participate in several investor conferences in New York City during September 2024. The events include the Morgan Stanley 22nd Annual Global Healthcare Conference, H.C. Wainwright 26th Annual Global Investment Conference, and the 2024 Cantor Fitzgerald Global Healthcare Conference. CEO Peter Luo will present insights on the company's developments, particularly their innovative SAFEbody technology that aims to enhance cancer immunotherapies. The presentations will be accessible via a live webcast.
Read more →ADAG▼ -7.5%on this news· ran to -18% by day 3
Adagene Reports Six Month Financial Results for 2024 and Provides Corporate Update - Potential best-in-class therapeutic index for lead candidate anti-CTLA-4 SAFEbody ADG126 (muzastotug) with higher, more frequent and re
Adagene Inc. has reported its financial results for the first half of 2024, showcasing a promising therapeutic index for its lead candidate, ADG126, when combined with Merck's KEYTRUDA. The company has a strong cash position of approximately $95.7 million, enabling streamlined operations through 2026. However, it recorded no revenue during the period and a significant increase in net loss. Further data and a poster presentation at the upcoming ESMO Congress will highlight ADG126's potential in treating metastatic colorectal cancer.
Read more →ADAGAdagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in September
Adagene Inc. announced a poster presentation at the upcoming ESMO Congress, scheduled for September 13-17, 2024, in Barcelona, Spain. The presentation will detail findings from an ongoing phase 1b/2 clinical trial of its masked anti-CTLA-4 SAFEbody, ADG126 (muzastotug), in combination with pembrolizumab for patients with metastatic MSS colorectal cancer. The study aims to demonstrate the safety and efficacy of this innovative therapy. Adagene's SAFEbody technology is designed to enhance targeting in the tumor microenvironment while reducing off-tumor toxicity.
Read more →ADAGAdagene to Present at Investor Conferences in June
Adagene Inc. announced its participation in several investor conferences in June 2024, where CEO Dr. Peter Luo will provide updates on the company's progress, particularly on its anti-CTLA-4 SAFEbody® ADG126. The conferences include those hosted by Jefferies and Goldman Sachs, among others. Adagene is focused on developing novel antibody-based cancer immunotherapies that utilize advanced precision technologies. The SAFEbody® technology aims to improve safety and efficacy in targeting cancer cells while reducing toxicity to healthy tissues.
Read more →ADAG▲ +15.7%on this news
Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update - Data for masked anti-CTLA-4 SAFEbody ADG126 (muzastotug) highlight best-in-class therapeutic index and demonstrate clinical benefits in met
Adagene Inc. has reported its 2023 financial results, highlighting advancements with its anti-CTLA-4 SAFEbody ADG126 in treating metastatic colorectal cancer. The company noted a significant improvement in clinical outcomes and demonstrated a new 20 mg/kg loading dose regimen during an expanded phase 2 trial. Financially, Adagene ended the year with a cash balance of approximately $110 million, which is expected to support operations through 2026, despite a reported net loss of $18.9 million. The company also made changes to its Board of Directors, reflecting ongoing strategic adjustments within its leadership.
Read more →ADAGAdagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board
Adagene Inc. has appointed Dr. Heinz-Josef Lenz to its Scientific and Strategic Advisory Board to strengthen its expertise in oncology, particularly colorectal cancer. Dr. Lenz, an established figure at USC Norris Comprehensive Cancer Center, emphasizes the importance of anti-CTLA-4 therapy in combination immunotherapy for treatment-resistant tumors like microsatellite stable colorectal cancer. His experience and ongoing research could enhance the development of Adagene's promising candidate, ADG126, which is currently in clinical trials.
Read more →ADAGAdagene to Present at the Leerink Partners Global Biopharma Conference 2024
Adagene Inc. has announced its participation in the Leerink Partners Global Biopharma Conference 2024, scheduled for March 11-13 in Miami, Florida. The company's CEO, Dr. Peter Luo, will present an update on their masked, anti-CTLA-4 SAFEbody® ADG126, highlighting key milestones expected for 2024. Adagene is focused on advancing novel antibody-based cancer immunotherapies and will also host investor meetings during the conference.
Read more →ADAG▲ +5.1%on this news
Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody ADG126 (muzastotug) in Combination with KEYTRUDA (pembrolizumab) to Demonstrate Further Efficacy in Patients wit
Adagene Inc. has announced significant progress in its clinical collaboration program for ADG126, a masked anti-CTLA-4 SAFEbody therapy, in combination with KEYTRUDA for metastatic colorectal cancer. The company plans to provide interim data regarding additional patients in 2024, following a dose expansion. Notably, Adagene has received clearance from China's Center for Drug Evaluation, allowing a broader evaluation of the drug. The focus will include a new dosing regimen aimed at enhancing efficacy while ensuring safety standards are met.
Read more →ADAG▲ +19.2%on this news
Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC) -
Adagene has presented interim results reinforcing the promising profile of its masked anti-CTLA-4 SAFEbody ADG126 in combination with pembrolizumab for patients with metastatic microsatellite-stable colorectal cancer. The data shows clinical benefit, including confirmed responses at higher doses, with a best-in-class median progression-free survival of seven months. This presentation was made at the ASCO 2024 Gastrointestinal Cancers Symposium and highlights the importance of ADG126 in addressing safety challenges associated with previous anti-CTLA-4 therapies. More patient data at the 10 mg/kg dosing regimen is expected throughout 2024.
Read more →ADAGAdagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium
Adagene Inc. announced it will present interim results of its anti-CTLA-4 SAFEbody ADG126 in combination with pembrolizumab during the ASCO GI Symposium. This study focuses on patients with metastatic microsatellite-stable colorectal cancer. The interim results indicate that the SAFEbody precision masking technology could redefine standards for anti-CTLA-4 therapies by addressing safety and efficacy issues. Detailed findings will be presented on January 20, 2024, in San Francisco.
Read more →ADAGAdagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody ADG126 at SITC 2023 - MSS CRC case examples reinforce optimal dosing regimen in ongoing phase 2 dose expansion, with
Adagene Inc. presented promising new data on its masked anti-CTLA-4 SAFEbody, ADG126, at the SITC 2023 meeting. The findings suggest that ADG126 may offer a best-in-class therapeutic index, particularly in the treatment of microsatellite stable colorectal cancer (MSS CRC). Notably, a clinical case demonstrated a confirmed partial response with the treatment regimen of ADG126 combined with pembrolizumab. While the data indicates a favorable safety profile, questions remain regarding the drug's long-term effectiveness and the company’s ability to secure future development funding and regulatory approvals.
Read more →ADAG▼ -6%on this news
Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
Adagene Inc. has announced a poster presentation focused on their candidate ADG126, a masked anti-CTLA-4 SAFEbody, at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) scheduled for November 1-5, 2023. The presentation will detail the optimal dosing strategy based on QSP modeling, including a regimen of 10 mg/kg every three weeks in combination with pembrolizumab for ongoing clinical studies. This presentation underscores Adagene's commitment to advancing novel cancer immunotherapies through innovative approaches.
Read more →ADAGAdagene to Present at Investor and Scientific Conferences in September
Adagene Inc. has announced its participation in significant upcoming investor and scientific conferences, including the Morgan Stanley and H.C. Wainwright events. CEO Dr. Peter Luo will engage with investors and present data on the promising safety and efficacy of the company's anti-CTLA-4 candidate, ADG126. Additionally, the company will participate in a SITC webinar focusing on the role of Treg depletion in cancer therapies. This indicates Adagene's proactive approach to showcasing its advancements in antibody-based therapies.
Read more →ADAG▲ +15.3%on this news
Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update - Best-in-class anti-CTLA-4 candidates designed for more than 30-fold increase in therapeutic index, addressing patient populations where
Adagene Inc. reported its financial results for the first half of 2023, highlighting its advancements in anti-CTLA-4 therapies. The company observed promising efficacy signals in ongoing clinical trials for SAFEbody ADG126, particularly in combination with pembrolizumab for metastatic colorectal cancer (MSS CRC). Despite a current cash balance of USD 128.8 million, Adagene experienced a net loss of USD 4.1 million during this period. The firm has made strategic updates to its board and is focused on expanding its clinical programs.
Read more →ADAGUnleashing Anti - CTLA - 4 Therapy By Enhancing the Therapeutic Index July 2023 Disclaimer and Cautionary Note on Forward - Looking Statements The following presentation has been prepared by Adagene Inc . ("Adagene" or t
Adagene Inc. is focusing on enhancing the therapeutic index of anti-CTLA-4 therapies through innovative strategies targeting the tumor microenvironment. Their two key candidates, ADG116 and ADG126, are currently in phase 1b/2 studies, showing promising results in efficacy and safety while treating various patient profiles. The company is engaged in collaborations that validate its proprietary technologies and has the potential to achieve significant milestone payments through these partnerships.
Read more →ADAGAdagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody Novel Masked Antibody-Drug Conjugate SAN DIEGO and
Adagene Inc. has successfully achieved a $3 million milestone as part of its collaboration with Exelixis for the development of novel masked antibody-drug conjugates using its proprietary SAFEbody technology. This milestone payment is part of a collaboration initiated in 2021, reflecting Adagene's continued focus on delivering high-quality antibody candidates. The SAFEbody technology is designed to improve cancer targeting while reducing toxicity in healthy tissues. This success further validates Adagene's antibody engineering capabilities and their efforts to secure non-dilutive funding through strategic partnerships.
Read more →ADAGAdagene Announces Updates to its Board of Directors SAN DIEGO and
Adagene Inc. has announced updates to its Board of Directors, welcoming Drs. Turner and Du and Ms. Wang. The appointment is aimed at advancing Adagene's clinical products and leveraging its platform technologies for growth. CEO Peter Luo expressed appreciation for past board member contributions while emphasizing the new directors' industry experience and insights. Adagene continues to focus on transforming antibody-based therapies, despite potential regulatory and operational challenges.
Read more →ADAGAdagene Presents Clinical Data for Anti-CTLA-4 SAFEbody ADG126 Reinforcing Best-in-Class Safety Profile at Repeat Doses and Showing Early Efficacy Profile in Advanced/Metastatic Solid Tumors - Results of dose escalation
Adagene Inc. (ADAG) presented promising interim results at the AACR Annual Meeting for their anti-CTLA-4 SAFEbody, ADG126, demonstrating a beneficial safety profile and initial signs of efficacy in advanced/metastatic solid tumors. The data were derived from phase 1b/2 trials involving different dosing regimens alongside anti-PD-1 therapies. Notably, the treatment exhibited minimal severe adverse events, positioning it as a potential leader in safety among similar therapies. The findings pave the way for further clinical trials aimed at exploring the drug's effectiveness in various cancer types.
Read more →ADAG▲ +5.8%on this news
March Adagene Reports Full Year 2022 Financial Results and Provides Corporate Update - Clinical data for wholly-owned anti-CTLA-4 franchise show best-in-class safety profiles for unmasked and masked candidates, unlocking
Adagene Inc. reported its full-year 2022 financial results, highlighting advancements in its anti-CTLA-4 franchise with promising safety profiles. The company has established collaborations with Sanofi and Exelixis, offering potential multi-billion dollar opportunities for non-dilutive funding. Adagene's cash balance stands at US$143.8 million, which is expected to support streamlined operations through 2025. Despite a rise in R&D expenses and an increased net loss, the company aims to leverage its proprietary SAFEbody technology in ongoing and future partnerships.
Read more →ADAG▲ +5.8%on this news
Adagene Reports Full Year 2022 Financial Results and Provides Corporate Update
Adagene Inc. reported its financial results for the full year 2022, emphasizing advancements in its anti-CTLA-4 franchise, particularly ADG116 and ADG126, which showed best-in-class safety profiles. The company announced collaborations with Roche, Sanofi, and Exelixis, presenting significant non-dilutive funding opportunities. Adagene's robust cash balance of $143.8 million is expected to sustain operations through 2025 while ongoing clinical trials are set to validate their SAFEbody technology.
Read more →ADAG▲ +5.1%on this news· ran to +18% by day 1
Adagene Announces Poster Presentations on Anti-CTLA-4 SAFEbody , ADG126, at Upcoming American Association for Cancer Research (AACR) Annual Meeting in April
Adagene Inc. announced poster presentations for two ongoing phase 1b/2 trials of its anti-CTLA-4 SAFEbody, ADG126, and preclinical data for ADG153 at the upcoming AACR Annual Meeting in April. The posters will detail safety and efficacy results in combination therapies with anti-PD-1 treatments. ADG153 has shown promising in vivo activity against solid tumors, with a focus on its differentiated profile amidst industry challenges. Adagene continues to leverage innovative technology in antibody-based cancer therapies.
Read more →ADAG▲ +11.3%on this news
Adagene Announces Interim Data Demonstrating Safety and Confirmed Clinical Responses of Anti-CTLA-4 SAFEbody ADG126 up to 10 mg/kg with Repeat Cycles in Combination with Anti-PD-1 Therapy from Dose Escalation Portion of
Adagene Inc. reported promising interim data on its anti-CTLA-4 SAFEbody ADG126, which showed a compelling safety profile and confirmed clinical responses in patients receiving the treatment in combination with anti-PD-1 therapy. The study found no dose-limiting toxicities and partial responses in various tumor types, particularly in hard-to-treat cold tumors. Ongoing dose expansion cohorts aim to optimize treatment as part of the FDA's Project Optimus initiative, with further data expected to be shared in 2023.
Read more →ADAG▲ +5.1%on this news· ran to +38% by day 3shared move
Adagene to Present at the Biotech Showcase™ 2023 in San Francisco on January 9
Adagene Inc. announced it will present a corporate update at the Biotech Showcase 2023 on January 9, 2023, in San Francisco. The presentation will be led by CEO Peter Luo and is part of a larger event coinciding with the J.P. Morgan Healthcare Conference. The company's cutting-edge approach combines computational biology and AI to develop novel antibody-based therapies for cancer. A live webcast of the event will be available on Adagene's website.
Read more →ADAG▲ +10.6%on this news
Adagene Announces Clinical Trial Collaboration to Evaluate Anti-CTLA-4 SAFEbody ADG126 in Combination with Roche's Standard-of-Care for First-Line Advanced Liver Cancer SAN DIEGO and
Announces Clinical Trial Collaboration to Evaluate Anti-CTLA-4 SAFEbody ADG126 in Combination with Roche's Standard-of-Care for First-Line Advanced Liver Cancer SAN DIEGO and SUZHOU, China, December 16, 2022 - Adagene Inc. ("Adagene") (Nasdaq: ADAG), a company transforming the
Read more →ADAGAdagene Appoints Cuong Do to Board of Directors and Audit Committee SAN DIEGO and
Adagene Appoints Cuong Do to Board of Directors SAN DIEGO and SUZHOU, China, November 21, 2022 - Adagene Inc. ("Adagene") (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Cuong Do, MBA, to Adag
Read more →ADAGAdagene Announces Clinical Data at SITC 2022 on Anti-CTLA-4 NEObody™, ADG116, Showing Differentiated Safety and Anti-tumor Activity in Heavily Pre-treated Patients with Difficult-to-Treat Tumors
- Interim phase 1b/2 data report safety profile of ADG116 across dosing levels, with repeat dosing of more than four cycles both as monotherapy and in combination with anti-PD-1 therapy - - Results include two partial responses as monotherapy in Kaposi’s sarcoma and renal cell c
Read more →ADAG▼ -7.6%on this news
Adagene Announces Poster Presentations on Anti-CTLA-4 NEObody™, ADG116, at Upcoming Society for Immunotherapy of Cancer’s (SITC) Annual Meeting in November
- NEObody technology platform enables dynamic targeting of a distinct epitope of CTLA-4 for enhanced safety and efficacy - - Data from phase 1b/2 studies in heavily pre-treated patients showcase differentiated safety profile of ADG116 across dosing levels, with repeat dosing bot
Read more →ADAGAdagene Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-Tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody ADG126 in Patients with Advanced Tumors - Best-in-class profile d
Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-Tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody ADG126 in Patients with Advanced Tumors profile demonstrated with repeat dosing across dose levels - - Antitumor activity observed in cold
Read more →ADAGAdagene Reports Financial Results for the Six Months Ended
Adagene Reports Financial Results for the Six Months Ended June 30, 2022 and Provides Corporate Updates - Topline data for anti-CTLA-4 antibody, ADG116, shows compelling clinical safety and complete and partial responses as both a single agent and in combination with anti-PD-
Read more →ADAGAdagene Announces Authorization of Share Repurchase Program up to US$10 Million SAN DIEGO, Calif. and
Adagene Announces Authorization of Share Repurchase Program up to US$10 Million SAN DIEGO, Calif. and SUZHOU, China, June 29, 2022 - Adagene Inc. ("Adagene") (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announce
Read more →ADAGAdagene Announces Publication at ASCO of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of Anti-CTLA-4 SAFEbody ADG126, with Repeat Dosing Across Dose Levels - First clinical data demonstratin
Adagene Announces Publication at ASCO of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of Anti-CTLA-4 SAFEbody ADG126, with Repeat Dosing Across Dose Levels - First clinical data demonstrating potential of SAFEbody technology platform to create be
Read more →ADAGAdagene to Participate in Investor Conferences in May and June
SAN DIEGO and SUZHOU, China, May 12, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that members of the company’s management will participate in the followin
Read more →ADAGAdagene Presents Data Demonstrating First and Best-in-Class Potential for Differentiated Preclinical Antibody Candidates at American Association for Cancer Research (AACR) Annual Meeting 2022 - Poster presentations showc
Adagene Presents Data Demonstrating First and Best-in-Class Potential for Differentiated Preclinical Antibody Candidates at American Association for Cancer Research (AACR) Annual Meeting 2022 presentations showcase SAFEbody precision masking technology applicability across t
Read more →ADAGAdagene Reports Full Year 2021 Financial Results and Provides Corporate Update - 2022 clinical data readouts on track to show potential best-in-class safety profile for anti-CTLA-4 programs (ADG116, ADG126) with PD-1 for
Adagene Reports Full Year 2021 Financial Results and Provides Corporate Update - 2022 clinical data readouts on track to show potential best-in-class safety profile for anti-CTLA-4 programs (ADG116, ADG126) with PD-1 for proven and new indications, thereby enabling greater ef
Read more →ADAGAdagene Announces FDA Clearance to Proceed with Phase 1b/2 Trial of Anti-CTLA-4 ADG126 SAFEbody in Combination Therapy With Anti-PD-1 Antibody Pembrolizumab - ADG126-P001 trial being initiated at multiple sites in U.S. a
Adagene Announces FDA Clearance to Proceed with Phase 1b/2 Trial of Anti-CTLA-4 ADG126 SAFEbody in Combination Therapy With Anti-PD-1 Antibody Pembrolizumab - ADG126-P001 trial being initiated at multiple sites in U.S. and Asia Pacific - - First SAFEbody candidate to advance
Read more →ADAGAdagene Announces Four Poster Presentations on Robust Preclinical Pipeline of Antibody-Based Therapeutics at Upcoming American Association for Cancer Research (AACR) Annual Meeting - New IND-enabling programs reinforce c
Adagene Announces Four Poster Presentations on Robust Preclinical Pipeline of Antibody-Based Therapeutics at Upcoming American Association for Cancer Research (AACR) Annual Meeting - New IND-enabling programs reinforce commitment to build a deep, broad and differentiated pipe
Read more →ADAGAdagene Announces SAFEbody Multi-Target Collaboration with Sanofi for Novel Masked Immuno-Oncology Antibody Candidates - Total potential transaction value of $2.5 billion plus royalties - SAN DIEGO and
Adagene Announces SAFEbody Multi-Target Collaboration with Sanofi for Novel Masked Immuno-Oncology Antibody Candidates - Total potential transaction value of $2.5 billion plus royalties - SAN DIEGO and SUZHOU, China, March 2, 2022 - Adagene Inc. ("Adagene") (Nasdaq: ADAG),
Read more →ADAGAdagene to Participate in the SVB Leerink 11th Annual Global Healthcare Conference
SAN DIEGO and SUZHOU, China, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that members of the company’s management will participate in one-on-one
Read more →ADAGAdagene Announces Board and Management Appointments to Support Pipeline Growth SAN DIEGO and
Board and Management Appointments to Support Pipeline Growth SAN DIEGO and SUZHOU, China, February 2, 2022 - Adagene Inc. ("Adagene") (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced board and management appointm
Read more →ADAGAdagene Announces First Patient Dosed with Novel, Proprietary Combination of Anti-CD137 Agonist, ADG106, and Anti-CTLA-4 Monoclonal Antibody, ADG116 SAN DIEGO and
Adagene Announces First Patient Dosed with Novel, Proprietary Combination of Anti-CD137 Agonist, ADG106, and Anti-CTLA-4 Monoclonal Antibody, ADG116 DIEGO and SUZHOU, China, January 27, 2022 - Adagene Inc. ("Adagene") (Nasdaq: ADAG), a company transforming the discovery and d
Read more →ADAGAdagene Expands Scientific and Strategic Advisory Board with Appointment of David Gandara, M.D. - Dr. Gandara, Professor and Senior Advisor to the Thoracic Oncology Program at University of California Davis, brings deep
Adagene Expands Scientific and Strategic Advisory Board with Appointment of David Gandara, M.D. - Dr. Gandara, Professor and Senior Advisor to the Thoracic Oncology Program at University of California Davis, brings deep expertise and strategic vision in cancer drug and biomar
Read more →ADAGAdagene Announces First Patients with Advanced Non-Small Cell Lung Cancer Dosed in Phase 1b/2 Clinical Trial of ADG106 in Combination with Nivolumab in Singapore - Clinical trial to be conducted at the National Universit
Adagene Announces First Patients with Advanced Non-Small Cell Lung Cancer Dosed in Phase 1b/2 Clinical Trial of ADG106 in Combination with Nivolumab in Singapore - Clinical trial to be conducted at the National University Cancer Institute, Singapore and the National Cancer Cen
Read more →ADAG▲ +5.5%on this newsshared move
Company Overview January 2022 Disclaimer and Cautionary Note on Forward - Looking Statements The following presentation has been prepared by Adagene Inc . (" Adagene " or the "Company") solely for informational purposes
Company Overview January 2022 Disclaimer and Cautionary Note on Forward - Looking Statements The following presentation has been prepared by Adagene Inc . (" Adagene " or the "Company") solely for informational purposes and should not be construed to be, directly or indirectly,
Read more →ADAG▼ -6.6%on this news
Adagene Achieves Key Milestone in Collaboration with Exelixis for SAFEbody Novel Masked Antibody-Drug Conjugate Candidates - Successful nomination of lead SAFEbody candidates triggers milestone payment - SAN DIEGO and
Adagene Achieves Key Milestone in Collaboration with Exelixis for SAFEbody Novel Masked Antibody-Drug Conjugate Candidates - Successful nomination of lead SAFEbody candidates triggers milestone payment - SAN DIEGO and SUZHOU, China, December 22, 2021 - Adagene Inc. ("Adagene
Read more →ADAG▼ -13.5%on this news
Adagene Presents Preclinical Data Showcasing Best-in-Class Profiles for ADG153, an Anti-CD47 SAFEbody and ADG152, a CD20xCD3 Bispecific T-cell Engager POWERbody - Posters presented at the 63 rd American Society of Hemato
Presents Preclinical Data Showcasing Best-in-Class Profiles for ADG153, an Anti-CD47 SAFEbody and ADG152, a CD20xCD3 Bispecific T-cell Engager POWERbody Posters presented at the 63rd American Society of Hematology Annual Meeting - DIEGO and SUZHOU, China, December 13, 2021 - A
Read more →ADAG▲ +6.4%on this news· ran to +28% by day 1
Adagene Presents Clinical Data Demonstrating Strong Safety and Early Signals of Efficacy in Cold Tumors Including Pancreatic and Ovarian Cancers for Anti-CTLA-4 Monoclonal Antibody, ADG116, at ESMO-IO 2021 - Additional h
Adagene Presents Clinical Data Demonstrating Strong Safety and Early Signals of Efficacy in Cold Tumors Including Pancreatic and Ovarian Cancers for Anti-CTLA-4 Monoclonal Antibody, ADG116, at ESMO-IO 2021 - Additional highlights include pharmacodynamic biomarker analyses fro
Read more →ADAGAdagene Announces FDA Clearance of IND for Phase 1b/2 Trial of Anti-CTLA-4 Monoclonal Antibody ADG116 in Combination Therapy with Anti-PD-1 Antibody Pembrolizumab - ADG116-P001 trial being initiated at multiple sites wit
Adagene Announces FDA Clearance of IND for Phase 1b/2 Trial of Anti-CTLA-4 Monoclonal Antibody ADG116 in Combination Therapy with Anti-PD-1 Antibody Pembrolizumab - ADG116-P001 trial being initiated at multiple sites with dosing to begin early 2022 - SAN DIEGO and SUZHOU, Ch
Read more →ADAGAdagene Announces Poster Presentations of Clinical Data for Two Novel Antibody Programs at ESMO Immuno-Oncology Congress 2021 SAN DIEGO and
Adagene Announces Poster Presentations of Clinical Antibody Programs at ESMO Immuno-Oncology Congress 2021 SAN DIEGO and SUZHOU, China, November 22, 2021 - Adagene Inc. ("Adagene") (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transfo
Read more →ADAGAdagene to Participate in Upcoming Investor & Industry Conferences in November
SAN DIEGO and SUZHOU, China, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced tha
Read more →ADAG▲ +5.5%on this newsshared move
Adagene Unveils Preclinical Data from Two Transformative Antibody Programs at Upcoming American Society of Hematology (ASH) Annual Meeting - Presentations demonstrate compelling preclinical differentiation of an anti-CD4
Unveils Preclinical Data from Two Transformative Antibody Programs at Upcoming American Society of Hematology (ASH) Annual Meeting Presentations demonstrate compelling preclinical differentiation of an anti-CD47 antibody and a CD20xCD3 bispecific T-cell engager, both leveragin
Read more →ADAGAdagene Establishes Collaboration for Clinical Trial of ADG106 in Combination with Nivolumab in Patients with Non-Small Cell Lung Cancer in Singapore - Phase 1b/2 trial to be conducted at the National University Cancer I
Adagene Establishes Collaboration for Clinical Trial of ADG106 in Combination with Nivolumab in Patients with Non-Small Cell Lung Cancer in Singapore - Phase 1b/2 trial to be conducted at the National University Cancer Institute, Singapore and the National Cancer Centre Sing
Read more →ADAGAdagene to Participate in the Jefferies Virtual China Biotech Summit
SAN FRANCISCO and SUZHOU, China, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced
Read more →ADAGAdagene to Participate at the Morgan Stanley 19th Annual Global Healthcare Conference
SAN FRANCISCO, Calif. and SUZHOU, China, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today
Read more →ADAGAdagene Announces the Third Clinical Trial Collaboration with Merck to Advance Anti-CD137 Agonist, ADG106, in Combination Therapy with KEYTRUDA (pembrolizumab) -Collaboration to evaluate NEObody product candidate, ADG106
Adagene Announces the Third Clinical Trial Collaboration with Merck to Advance Anti-CD137 Agonist, ADG106, in Combination Therapy with KEYTRUDA (pembrolizumab) -Collaboration to evaluate NEObody product candidate, ADG106, in combination with KEYTRUDA for patients with advanc
Read more →ADAGAdagene Announces Appointment of Interim Chief Medical Officer and New Members of Scientific and Strategic Advisory Board - Global immuno-oncology experts bring decades of experience to advance company's transformative r
Adagene Announces Appointment of Interim Chief Medical Officer and New Members of Scientific and Strategic Advisory Board - Global immuno-oncology experts bring decades of experience to advance company's transformative research and development pipeline - SAN FRANCISCO, Cali
Read more →ADAGAdagene Announces Clinical Trial Collaboration With Merck to Advance Two Anti-CTLA-4 Monoclonal Antibody Programs (ADG116 and ADG126) in Combination Therapy with KEYTRUDA (pembrolizumab) - Two global clinical studies to
Adagene Announces Clinical Trial Collaboration With Merck to Advance Two Anti-CTLA-4 Monoclonal Antibody Programs (ADG116 and ADG126) in Combination Therapy with KEYTRUDA - Two global clinical studies to evaluate NEObody product candidate, ADG116, and SAFEbody product candid
Read more →ADAGAdagene Announces Authorization of Share Repurchase Program up to US$20 Million SAN FRANCISCO, Calif. and
Adagene Announces Authorization of Share Repurchase Program up to US$20 Million SAN FRANCISCO, Calif. and SUZHOU, China, July 7, 2021 - Adagene Inc. ("Adagene") (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery
Read more →ADAGAdagene Announces Inclusion in FTSE Russell Indexes
SAN FRANCISCO and SUZHOU, China, June 16, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announce
Read more →ADAGAdagene to Present at Upcoming Investor Conferences
SAN FRANCISCO, Calif. and SUZHOU, China, May 25, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today an
Read more →ADAGAdagene Presents Clinical Data from NEObody™ Program, ADG106, Anti-CD137 Agonist, in an Abstract at ASCO 2021 Annual Meeting
-Identified a predictive biomarker and two pharmacodynamic biomarkers that correlate with clinical efficacy and target engagement -ADG106, a fully human, ligand-blocking, agonistic anti-CD137 antibody demonstrated a favorable safety profile SAN FRANCISCO and SUZHOU, China, May
Read more →ADAGAdagene Presents Clinical Data from NEObody TM Program, ADG106, Anti-CD137 Agonist, in an Abstract at ASCO 2021 Annual Meeting -Identified a predictive biomarker and two pharmacodynamic biomarkers that correlate with cli
Adagene Presents Clinical Data from NEObodyTM Program, ADG106, Anti-CD137 Agonist, in an Abstract at ASCO 2021 Annual Meeting a predictive biomarker and two pharmacodynamic biomarkers that correlate with clinical efficacy and target engagement -ADG106, a fully human, ligand-bl
Read more →ADAGAdagene Presents Preclinical Data from Lead SAFEbody TM Program, ADG126, at the American Association for Cancer Research (AACR) Annual Meeting 2021 SAN FRANCISCO, Calif. and
Adagene Presents Preclinical Data from Lead SAFEbodyTM Program, ADG126, at the American Association for Cancer Research (AACR) Annual Meeting 2021 SAN FRANCISCO, Calif. and SUZHOU, China, April 13, 2021 Adagene Inc. ( Adagene ) (Nasdaq: ADAG), a platform-driven, clinical-stage
Read more →ADAGAdagene Reports Full Year 2020 Financial Results and Provides Corporate Updates - Successfully completed Initial Public Offering raising approximately US$161 million in gross proceeds- -Reported clinical data for anti-CD
Adagene Reports Full Year 2020 Financial Results and Provides Corporate Updates - Successfully completed Initial Public Offering raising approximately US$161 million in gross proceeds- -Reported clinical data for anti-CD137 and two anti-CTLA-4 programs- -Advanced five discover
Read more →ADAGAdagene Announces Clinical Advancement for ADG116
-NEObody™ product candidate ADG116 has been well tolerated in ongoing Phase 1 clinical trial- -Promising pharmacodynamic biomarker signals demonstrate clinical proof of mechanism- -Poised for global expansion- SAN FRANCISCO and SUZHOU, China, March 29, 2021 (GLOBE NEWSWIRE) --
Read more →ADAGAdagene Announces Clinical Advancement for ADG116 -NEObody product candidate ADG116 has been well tolerated in ongoing Phase 1 clinical trial- - Promising pharmacodynamic biomarker signals demonstrate clinical proof of m
Adagene Announces Clinical Advancement for ADG116 -NEObody product candidate ADG116 has been well tolerated in ongoing Phase 1 clinical trial- - Promising pharmacodynamic biomarker signals demonstrate clinical proof of mechanism- -Poised for global expansion- SAN FRANCISCO, C
Read more →ADAGAdagene Announces First Patients Dosed in Global Phase 1 Clinical Trial of ADG126, Lead SAFEbody Program -SAFEbody technology enables precision masking of antibodies for enhanced safety- SAN FRANCISCO, Calif. and
Adagene Announces First Patients Dosed in Global Phase 1 Clinical Trial of ADG126, Lead SAFEbody Program -SAFEbody technology enables precision masking of antibodies for enhanced safety- SAN FRANCISCO, Calif. and SUZHOU, China, March 16, 2021 Adagene Inc. ( Adagene ) (Nasdaq: A
Read more →ADAGAdagene Inc. Announces Closing of Initial Public Offering and Exercise of Underwriters' Over-Allotment Option
SAN FRANCISCO, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene" or the "Company") (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies, today ann
Read more →ADAGAdagene Inc. Announces Pricing of Initial Public Offering
SAN FRANCISCO, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene" or the "Company") (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies, t
Read more →ADAGAdagene Announces Milestone of CAR-T Collaboration with the National Heart, Lung, and Blood Institute at the National Institutes of Health
- Collaboration with Richard Childs, M.D., yields potential first-ever antibodies targeting human endogenous retrovirus associated with renal cell carcinoma SAN FRANCISCO, Calif. and SUZHOU, China, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Adagene, Inc., a platform-driven, clinical-stag
Read more →ADAGAdagene Announces Expansion of Leadership Team to Support Strategic Growth
Hua Gong, M.D., Ph.D., appointed Chief Operating Officer and Head of Precision Medicine JC Xu, M.D., Ph.D., appointed Chief Scientific Officer Qinghai Zhao, Ph.D., appointed Chief Manufacturing Officer Company establishes presence in San Diego as a Center of Excellence for Pre
Read more →ADAGAdagene to Present at the 38th Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO and SUZHOU, China, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Adagene, Inc., a clinical-stage, leading-edge oncology immunotherapy company driven by a powerful antibody discovery and engineering platform, today announced that Peter Luo, Ph.D., Co-founder and Chief Executive
Read more →ADAGAdagene Completes $69 Million Series D Financing Led by Growth Investor General Atlantic
SAN FRANCISCO and SUZHOU, China, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Adagene, Inc., a clinical-stage, leading-edge oncology immunotherapy company driven by a powerful antibody discovery and engineering platform, today announced the completion of a $69 million Series D financing, in
Read more →Competitive Position
How ADAG ranks across every disease it competes inCompetitive Position is a premium feature
See how ADAG ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial